← Eichor
Study identifier: NCT04258449 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

DOvEEgene Fleur: New Uterine Sampling Tool

Condition: Women With Suspected or Confirmed Gynecological Disease  ·  Sponsor: McGill University

PhaseN/A
Planned participants40
Who can joinFemale, 18 Years to no upper limit
Healthy volunteersNo

About this study

This study is related to a previous study from the same group which started in 2014 (NTC02288676, McGill REB A08-M79-13B, MUHC REB 2020-5945) to develop a clinically implementable screening test -DovEEgene: developing and validating a novel molecular test for the early diagnosis of cancer of the endometrium, tubes and ovaries. This study is designed to identify endometrial, tubal and ovarian cancer very early based on identifying cancer-specific mutations (cancer DNA) in a pap sample taken from inside the uterus. The results are particularly encouraging given that control group is challenging with high background mutational burden from benign tumours, endometriosis, germ-line mutations etc. To date, all the intrauterine samples were obtained using the commercially available TAO brush™ which is designed to take an endometrial sample. However, when patient tolerability was assessed using a numerical pain scale (NPS) ranging from 0 (no pain) to 10 (severe pain), patients rated the sampling using the TAO brush™ at 3.5 versus 0 for a cervical pap sample. These results were not surprising as the TAO brush™ was designed for dislodging strips of endometrial tissue to use for histopathologic examination. With respect to the investigators objective, which is to collect cancer cells that have exfoliated to the uterus, a sampler that collects these exfoliated cells with as little disturbance as possible to the underlying endometrium is preferred. In this sub-study, the investigators aim…

This description comes directly from the study's public registry record.

Talk to the study team

Dr. Lucy Gilbert, MD,MSc,FRCOG  ·  (514) 934-1934  ·  lucy.gilbert@mcgill.ca

Dr. Claudia Martins, PhD  ·  (514) 934-1934  ·  claudia.martins@mcgill.ca

Always discuss trial participation with your own doctor first.

Locations (1)

Royal Victoria Hospital (Glen Site)Montreal, Quebec, CanadaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04258449